KILITCH DRUGS (INDIA) LTD. - 524500 - Clarification sought from Kilitch Drugs India Ltd
The Exchange has sought clarification from Kilitch Drugs India Ltd on June 15, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. KILITCH DRUGS (INDIA) LTD. - 524500 - Outcome Of Board Meeting Held On May 25, 2020
Dear Sir/Madam, In continuation to our letter dated May 20th 2020, we wish to inform you that pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 25th May, 2020, have considered & approved the Allotment of 44883 Equity shares pursuant to exercise of option granted to employees of the Company under ESOS Scheme. The meeting commenced at 10:00 A.M. and concluded at 12:00 P.M. The above is for information and dissemination to the public at large. KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Consideration Of The Allotment Of Equity Shares Pursuant To Exercise Of Option Granted To Employees Of The Company Under ESOS Scheme
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2020 ,inter alia, to consider and approve the allotment of Equity Shares pursuant to exercise of option granted to employees of the Company under ESOS Scheme. KILITCH DRUGS (INDIA) LTD. - 524500 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
With reference to Regulation 40(9) of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find attached herewith the certificate dated 14th May, 2020 received from M/s. Deep Shukla & Associates, Practicing Company Secretaries for the half year ended 31st March 2020. KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith certificate issued by the Registrar & Share Transfer Agent M/s. Link Intime India Private Limited confirming the compliance of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 KILITCH DRUGS (INDIA) LTD. - 524500 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshal Anant PatilDesignation :- Company Secretary and Compliance Officer KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholding for the Period Ended March 31, 2020
Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here KILITCH DRUGS (INDIA) LTD. - 524500 - Compliance Certificate Pursuant To The Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2020
Please find enclosed Compliance Certificate pursuant to the Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2020. KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Disclosure Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 KILITCH DRUGS (INDIA) LTD. - 524500 - Reply To The Clarification Sought On Price Movement Of The Shares Of The Company.
Reply To The Clarification Sought On Price Movement Of The Shares Of The Company.